Business
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, Univ
About this update from Minerva Neurosciences, Inc
[{"type":"image","alt":"Minerva Neurosciences, Inc","displaySize":"","headline":null,"caption":"Minerva Neurosciences, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":266,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/f60fa0c3e62cef59eace336fa54bcafa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MZ8bz5E62EziAC2QyixjbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f60fa0c3e62cef59eace336fa54bcafa","width":266,"height":83}},"lazy":false},{"type":"text","content":"BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, University of Arkansas for Medical Sciences). They will join the company management team to elaborate on the patient burden of the negative symptoms of schizophrenia, the challenges associated with assessing negative symptoms in the current regulatory environment and how the company’s upcoming Phase 3 trial of roluperidone is expected to meet those challenges.","length":858,"tagName":"p"},{"type":"text","content":"To register, click here.","length":24,"tagName":"p"},{"type":"text","content":"Current antipsychotics do not adequately treat the negative symptoms of schizophrenia despite decades of clinical trials and myriad FDA approvals. Recognizing there has never been a drug approved specifically for negative symptoms, FDA hosted a public meeting in August 2024 to establish the optimal approach in clinical trials. Minerva plans to start a confirmatory Phase 3 trial in 2026 utilizing a novel protocol, which is aligned with FDA considerations and designed to maximize the probability of a successful outcome.","length":523,"tagName":"p"},{"type":"text","content":"A live question and answer session will follow the formal presentations.","length":72,"tagName":"p"},{"type":"text","content":"About Gregory Strauss, PhDGregory Strauss, PhD, is the Franklin Professor of Psychology and Neuroscience at the University of Geo...